1
|
Gaikwad SS, Nimal SK, Pol R, Markad D, Jadhao AR, Jadhav U, Kate AN, Gacche RN, Patil LR, Chikate RC. Targeting AKT2 in MDA-MB-231 Cells by Pyrazole Hybrids: Structural, Biological and Molecular Docking Studies. Chem Biodivers 2023; 20:e202300799. [PMID: 37702285 DOI: 10.1002/cbdv.202300799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 08/30/2023] [Accepted: 09/11/2023] [Indexed: 09/14/2023]
Abstract
Pyrazolic hybrids appended with naphthalene, p-chlorobenzene, o-phenol and toluene have been synthesized using Claisen Schmidt condensation reaction of 1-benzyl-3,5-dimethyl-1H-pyrazole-4-carbaldehyde. All compounds were characterized by various spectroscopic techniques. Compound (E)-3-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)-1-(4-chlorophenyl)prop-2-en-1-one crystallizes in monoclinic crystal system with C2/c space group. These synthesized compounds were tested for cytotoxic activity and among these compounds 4b and 5a shows prominent cytotoxic activity against triple-negative breast cancer (TNBC) cells MDA-MB-231 with IC50 values 47.72 μM and 24.25 μM, respectively. Distinguishing morphological changes were noticed in MDA-MB-231 cells treated with pyrazole hybrids contributing to apoptosis action. To get more insight into cytotoxic activity, in silico molecular docking of these compounds were performed and the results suggested that (E)-3-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)-1-(p-tolyl)prop-2-en-1-one and 1-(1'-benzyl-5-(4-chlorophenyl)-3',5'-dimethyl-3,4-dihydro-1'H,2H-[3,4'-bipyrazol]-2-yl)ethan-1-one binds to the prominent domain of Akt2 indicating their potential ability as Akt2 inhibitor. Moreover, from in silico ADME studies clearly demonstrated that these compounds may be regarded as a drug candidate for sub-lingual absorption based on log p values (2.157-4.924). These compounds also show promising antitubercular activity. The overall results suggest that pyrazolic hybrids with substitution at less sterically hindered positions have appealing potent cytotoxic activity and antituberculosis activity due to which they may act as multidrug candidate.
Collapse
Affiliation(s)
- Sanjay S Gaikwad
- Department of Chemistry, MES, Abasaheb Garware College, Pune, Maharashtra, India-, 411004
| | - Snehal K Nimal
- Department of Biotechnology, Savitribai Phule Pune University, Pune, Maharashtra, India-, 411007
| | - Rushikesh Pol
- Department of Microbiology, Savitribai Phule Pune University, Pune, Maharashtra, India-, 411007
| | - Datta Markad
- Department of Chemistry, University of Liverpool, Liverpool, L69 7ZD, United Kingdom
| | - Amardeep R Jadhao
- Department of Chemistry, Late Pushpadevi Patil Arts and Science College, Risod, Dist., Washim, Maharashtra, India-, 444506
| | - Umesh Jadhav
- Department of Microbiology, Savitribai Phule Pune University, Pune, Maharashtra, India-, 411007
| | - Anup N Kate
- Department of Chemistry, MES, Abasaheb Garware College, Pune, Maharashtra, India-, 411004
| | - Rajesh N Gacche
- Department of Biotechnology, Savitribai Phule Pune University, Pune, Maharashtra, India-, 411007
| | - Limbraj R Patil
- Department of Chemistry, Maharaja Jivajirao Shinde Arts, Science, Commerce, College, Shrigonda, Maharashtra, India-, 413701
| | - Rajeev C Chikate
- Department of Chemistry, MES, Abasaheb Garware College, Pune, Maharashtra, India-, 411004
| |
Collapse
|
2
|
Pujol A, Sanchis P, Grases F, Masmiquel L. Phytate Intake, Health and Disease: "Let Thy Food Be Thy Medicine and Medicine Be Thy Food". Antioxidants (Basel) 2023; 12:antiox12010146. [PMID: 36671007 PMCID: PMC9855079 DOI: 10.3390/antiox12010146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Revised: 01/04/2023] [Accepted: 01/05/2023] [Indexed: 01/11/2023] Open
Abstract
Phytate (myo-inositol hexakisphosphate or InsP6) is the main phosphorus reservoir that is present in almost all wholegrains, legumes, and oilseeds. It is a major component of the Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diets. Phytate is recognized as a nutraceutical and is classified by the Food and Drug Administration (FDA) as Generally Recognized As Safe (GRAS). Phytate has been shown to be effective in treating or preventing certain diseases. Phytate has been shown to inhibit calcium salt crystallization and, therefore, to reduce vascular calcifications, calcium renal calculi and soft tissue calcifications. Moreover, the adsorption of phytate to the crystal faces can inhibit hydroxyapatite dissolution and bone resorption, thereby playing a role in the treatment/prevention of bone mass loss. Phytate has a potent antioxidation and anti-inflammatory action. It is capable of inhibiting lipid peroxidation through iron chelation, reducing iron-related free radical generation. As this has the effect of mitigating neuronal damage and loss, phytate shows promise in the treatment/prevention of neurodegenerative disease. It is reported that phytate improves lipid and carbohydrate metabolism, increases adiponectin, decreases leptin and reduces protein glycation, which is linked with macrovascular and microvascular diabetes complications. In this review, we summarize the benefits of phytate intake as seen in in vitro, animal model, epidemiological and clinical trials, and we also identify questions to answer in the future.
Collapse
Affiliation(s)
- Antelm Pujol
- Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa), 07198 Palma de Mallorca, Spain
- Correspondence: (A.P.); (L.M.)
| | - Pilar Sanchis
- Laboratory of Renal Lithiasis Research, Deptartment of Chemistry, University of Balearic Islands, Health Research Institute of Balearic Islands, (IdISBa), 07122 Palma de Mallorca, Spain
| | - Felix Grases
- Laboratory of Renal Lithiasis Research, Deptartment of Chemistry, University of Balearic Islands, Health Research Institute of Balearic Islands, (IdISBa), 07122 Palma de Mallorca, Spain
| | - Luis Masmiquel
- Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa), 07198 Palma de Mallorca, Spain
- Correspondence: (A.P.); (L.M.)
| |
Collapse
|
3
|
Vucenik I, Druzijanic A, Druzijanic N. Inositol Hexaphosphate (IP6) and Colon Cancer: From Concepts and First Experiments to Clinical Application. Molecules 2020; 25:E5931. [PMID: 33333775 PMCID: PMC7765177 DOI: 10.3390/molecules25245931] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Revised: 12/07/2020] [Accepted: 12/12/2020] [Indexed: 12/14/2022] Open
Abstract
Multiple human health-beneficial effects have been related to highly phosphorylated inositol hexaphosphate (IP6). This naturally occurring carbohydrate and its parent compound, myo-inositol (Ins), are abundantly present in plants, particularly in certain high-fiber diets, but also in mammalian cells, where they regulate important cellular functions. However, the striking and broad-spectrum anticancer activity of IP6, consistently demonstrated in different experimental models, has been in a spotlight of the scientific community dealing with the nutrition and cancer during the last several decades. First experiments were performed in colon cancer 30 years ago. Since then, it has been shown that IP6 reduces cell proliferation, induces apoptosis and differentiation of malignant cells with reversion to normal phenotype, affecting several critical molecular targets. Enhanced immunity and antioxidant properties also contribute to the tumor cell destruction. Although Ins possesses a modest anticancer potential, the best anticancer results were obtained from the combination of IP6 + Ins. Here we review the first experimental steps in colon cancer, when concepts and hypotheses were put together almost without real knowledge and present clinical studies, that were initiated in colon cancer patients. Available as a dietary supplement, IP6 + Ins has been shown to enhance the anticancer effect of conventional chemotherapy, controls cancer metastases, and improves quality of life in cancer patients. Emerging clinical and still vast amount of experimental data suggest its role either as an adjuvant or as an "alternative" to current chemotherapy for cancer.
Collapse
Affiliation(s)
- Ivana Vucenik
- Department of Medical and Research Technology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
- Department of Pathology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA
| | - Ana Druzijanic
- Department of Oral Medicine and Periodontology, School of Medicine, Dental Medicine, University of Split, 21000 Split, Croatia;
| | - Nikica Druzijanic
- Department of Surgery, University Hospital Split, School of Medicine, University of Split, 21000 Split, Croatia;
| |
Collapse
|
4
|
Galbraith AR, Seabloom DE, Wuertz BR, Antonides JD, Steele VE, Wattenberg LW, Ondrey FG. Chemoprevention of Lung Carcinogenesis by Dietary Nicotinamide and Inhaled Budesonide. Cancer Prev Res (Phila) 2019; 12:69-78. [PMID: 30606719 DOI: 10.1158/1940-6207.capr-17-0402] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2017] [Revised: 05/17/2018] [Accepted: 12/18/2018] [Indexed: 11/16/2022]
Abstract
Nicotinamide, the amide form of vitamin B3, and budesonide, a synthetic glucocorticoid used in the treatment of asthma, were evaluated to determine their individual and combinational chemopreventive efficacy on benzo(a)pyrene-induced lung tumors in female A/J mice. Nicotinamide fed at a dietary concentration of 0.75% significantly inhibited tumor multiplicity. Nicotinamide by aerosol inhalation at doses up to 15 mg/kg/day did not result in a statistically significant reduction in tumor multiplicity. Finally, dietary nicotinamide was administered with aerosol budesonide and tumor multiplicity reduced by 90% at 1 week and 49% at 8 weeks post last carcinogen dose. We conclude nicotinamide is an effective and safe agent for lung cancer dietary prevention at both early- and late-stage carcinogenesis and that efficacy is increased with aerosol budesonide. Combination chemoprevention with these agents is a well-tolerated and effective strategy which could be clinically advanced to human studies.
Collapse
Affiliation(s)
- Arthur R Galbraith
- Carcinogenesis and Chemoprevention Research Program, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
| | - Donna E Seabloom
- AeroCore Testing Services, Department of Otolaryngology, University of Minnesota, Minneapolis, Minnesota.,Department of Otolaryngology, Medical School, University of Minnesota, Minneapolis, Minnesota
| | - Beverly R Wuertz
- AeroCore Testing Services, Department of Otolaryngology, University of Minnesota, Minneapolis, Minnesota.,Department of Otolaryngology, Medical School, University of Minnesota, Minneapolis, Minnesota
| | - Jennifer D Antonides
- Carcinogenesis and Chemoprevention Research Program, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
| | - Vernon E Steele
- Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland
| | - Lee W Wattenberg
- Carcinogenesis and Chemoprevention Research Program, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
| | - Frank G Ondrey
- Carcinogenesis and Chemoprevention Research Program, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. .,AeroCore Testing Services, Department of Otolaryngology, University of Minnesota, Minneapolis, Minnesota.,Department of Otolaryngology, Medical School, University of Minnesota, Minneapolis, Minnesota
| |
Collapse
|
5
|
Sankappa Rai U, Isloor A, Shetty P, Pai K, Fun H. Synthesis and in vitro biological evaluation of new pyrazole chalcones and heterocyclic diamides as potential anticancer agents. ARAB J CHEM 2015. [DOI: 10.1016/j.arabjc.2014.01.018] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
6
|
Seidel C, Schnekenburger M, Zwergel C, Gaascht F, Mai A, Dicato M, Kirsch G, Valente S, Diederich M. Novel inhibitors of human histone deacetylases: Design, synthesis and bioactivity of 3-alkenoylcoumarines. Bioorg Med Chem Lett 2014; 24:3797-801. [DOI: 10.1016/j.bmcl.2014.06.067] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2014] [Revised: 06/19/2014] [Accepted: 06/21/2014] [Indexed: 12/19/2022]
|
7
|
Chauhan SS, Singh AK, Meena S, Lohani M, Singh A, Arya RK, Cheruvu SH, Sarkar J, Gayen JR, Datta D, Chauhan PMS. Synthesis of novel β-carboline based chalcones with high cytotoxic activity against breast cancer cells. Bioorg Med Chem Lett 2014; 24:2820-4. [PMID: 24844196 DOI: 10.1016/j.bmcl.2014.04.109] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2014] [Revised: 04/23/2014] [Accepted: 04/26/2014] [Indexed: 10/25/2022]
Abstract
A series of novel β-carboline based chalcones was synthesized and evaluated for their cytotoxic activity against a panel of human cancer cell lines. Among them we found that two of the compounds 7c and 7d, showed marked anti-proliferative activity in a panel of solid tumor cell lines with highest effect in breast cancer. The compounds 7c and 7d showed an IC50 of 2.25 and 3.29 μM, respectively against human breast cancer MCF-7 cell line. Further, the compound 7c markedly induced DNA fragmentation and apoptosis in breast cancer cells.
Collapse
Affiliation(s)
- Shikha S Chauhan
- Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Lucknow 226031, India; Department of Chemistry, Integral University, Lucknow 226 026, U.P., India
| | - Anup K Singh
- Biochemistry Division, CSIR-Central Drug Research Institute, Lucknow 226031, India
| | - Sanjeev Meena
- Biochemistry Division, CSIR-Central Drug Research Institute, Lucknow 226031, India
| | - Minaxi Lohani
- Department of Chemistry, Integral University, Lucknow 226 026, U.P., India
| | - Akhilesh Singh
- Biochemistry Division, CSIR-Central Drug Research Institute, Lucknow 226031, India
| | - Rakesh K Arya
- Biochemistry Division, CSIR-Central Drug Research Institute, Lucknow 226031, India
| | - Srikanth H Cheruvu
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, India
| | - Jayanta Sarkar
- Biochemistry Division, CSIR-Central Drug Research Institute, Lucknow 226031, India
| | - Jiaur R Gayen
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, India
| | - Dipak Datta
- Biochemistry Division, CSIR-Central Drug Research Institute, Lucknow 226031, India
| | - Prem M S Chauhan
- Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Lucknow 226031, India.
| |
Collapse
|
8
|
Singh R, Rawat P, Sahu S. A mixed experimental and DFT study on ethyl 4-[3-(4-dimethylamino-phenyl)-acryloyl]-3,5-dimethyl-1H-pyrrole-2-carboxylate. J Mol Struct 2014. [DOI: 10.1016/j.molstruc.2014.02.041] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
9
|
Gaur R, Mishra L. Synthesis and Characterization of Ru(II)–DMSO–Cl–Chalcone Complexes: DNA Binding, Nuclease, and Topoisomerase II Inhibitory Activity. Inorg Chem 2012; 51:3059-70. [DOI: 10.1021/ic202440r] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Ruchi Gaur
- Department of Chemistry, Faculty of Science, Banaras Hindu University, Varanasi-221005, India
| | - Lallan Mishra
- Department of Chemistry, Faculty of Science, Banaras Hindu University, Varanasi-221005, India
| |
Collapse
|
10
|
Wu D, Sullards MC, Oldham CD, Gelbaum L, Lucrezi J, Pullman GS, May SW. Myo-inositol hexakisphosphate, isolated from female gametophyte tissue of loblolly pine, inhibits growth of early-stage somatic embryos. THE NEW PHYTOLOGIST 2012; 193:313-326. [PMID: 22023391 DOI: 10.1111/j.1469-8137.2011.03928.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
• Myo-inositol hexakisphosphate (InsP(6)), abundant in animals and plants, is well known for its anticancer activity. However, many aspects of InsP(6) function in plants remain undefined. We now report the first evidence that InsP(6) can inhibit cellular proliferation in plants under growth conditions where phosphorus is not limited. • A highly anionic molecule inhibitory to early-stage somatic embryo growth of loblolly pine (LP) was purified chromatographically from late-stage LP female gametophytes (FGs), and then characterized structurally using mass spectrometry (MS) and nuclear magnetic resonance (NMR) analyses. • Exact mass and mass spectrometry-mass spectrometry (MS-MS) fragmentation identified the bioactive molecule as an inositol hexakisphosphate. It was then identified as the myo-isomer (i.e. InsP(6)) on the basis of (1)H-, (31)P- and (13)C-NMR, (1)H-(1)H correlation spectroscopy (COSY), (1)H-(31)P heteronuclear single quantum correlation (HSQC) and (1)H-(13)C HSQC. Topical application of InsP(6) to early-stage somatic embryos indeed inhibits embryonic growth. • Recently evidence has begun to emerge that InsP(6) may also play a regulatory role in plant cells. We anticipate that our findings will help to stimulate additional investigations aimed at elucidating the roles of inositol phosphates in cellular growth and development in plants.
Collapse
Affiliation(s)
- Di Wu
- School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | | | | | | | | | | | | |
Collapse
|
11
|
Sharma A, Chakravarti B, Gupt MP, Siddiqui JA, Konwar R, Tripathi RP. Synthesis and anti breast cancer activity of biphenyl based chalcones. Bioorg Med Chem 2010; 18:4711-20. [PMID: 20605470 DOI: 10.1016/j.bmc.2010.05.015] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2010] [Revised: 05/04/2010] [Accepted: 05/05/2010] [Indexed: 02/02/2023]
Abstract
A series of (2E,2'E)-1,1'-(3-hydroxy-5-methylbiphenyl-2,6-diyl)-bis(3-pheylprop-2-ene-1-ones (5-33) were prepared by the reaction of 1,3-diacetyl biphenyls (1-4) with different aldehydes in presence of catalytic amount of solid KOH in ethanol in excellent yields. The compounds were evaluated for anticancer activity against human breast cancer MCF-7 (estrogen responsive proliferative breast cancer model) and MDA-MB-231 (estrogen independent aggressive breast cancer model) cell lines, HeLa (cervical cancer) cell line, and human embryonic kidney (HEK-293) cells. Most of the compounds preferentially inhibited the growth of the aggressive human breast cancer cell lines, MDA-MB-231 in the range of 4.4-30 μM. The two compounds 9 and 29 proved to be better anticancer agents than the standard drug tamoxifen against the MDA-MB-231 cell lines. Mode of action of these compounds was established to be apoptosis, cell cycle arrest and loss of mitochondrial membrane potential.
Collapse
Affiliation(s)
- Anindra Sharma
- Medicinal and Process Chemistry Division, Central Drug Research Institute (CSIR), Lucknow 226001, India
| | | | | | | | | | | |
Collapse
|
12
|
Ratković Z, Juranić ZD, Stanojković T, Manojlović D, Vukićević RD, Radulović N, Joksović MD. Synthesis, characterization, electrochemical studies and antitumor activity of some new chalcone analogues containing ferrocenyl pyrazole moiety. Bioorg Chem 2010; 38:26-32. [DOI: 10.1016/j.bioorg.2009.09.003] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2009] [Revised: 09/23/2009] [Accepted: 09/24/2009] [Indexed: 10/20/2022]
|
13
|
Srinivasan B, Johnson TE, Lad R, Xing C. Structure−Activity Relationship Studies of Chalcone Leading to 3-Hydroxy-4,3′,4′,5′-tetramethoxychalcone and Its Analogues as Potent Nuclear Factor κB Inhibitors and Their Anticancer Activities. J Med Chem 2009; 52:7228-35. [DOI: 10.1021/jm901278z] [Citation(s) in RCA: 128] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Balasubramanian Srinivasan
- Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455
| | - Thomas E. Johnson
- Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455
| | - Rahul Lad
- Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455
| | - Chengguo Xing
- Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455
| |
Collapse
|
14
|
Abstract
Inositol hexaphosphate (IP(6)) is a naturally occurring polyphosphorylated carbohydrate, abundantly present in many plant sources and in certain high-fiber diets, such as cereals and legumes. In addition to being found in plants, IP(6) is contained in almost all mammalian cells, although in much smaller amounts, where it is important in regulating vital cellular functions such as signal transduction, cell proliferation, and differentiation. For a long time IP(6) has been recognized as a natural antioxidant. Recently IP(6) has received much attention for its role in cancer prevention and control of experimental tumor growth, progression, and metastasis. In addition, IP(6) possesses other significant benefits for human health, such as the ability to enhance immune system, prevent pathological calcification and kidney stone formation, lower elevated serum cholesterol, and reduce pathological platelet activity. In this review we show the efficacy and discuss some of the molecular mechanisms that govern the action of this dietary agent. Exogenously administered IP(6) is rapidly taken up into cells and dephosphorylated to lower inositol phosphates, which further affect signal transduction pathways resulting in cell cycle arrest. A striking anticancer action of IP(6) was demonstrated in different experimental models. In addition to reducing cell proliferation, IP(6) also induces differentiation of malignant cells. Enhanced immunity and antioxidant properties also contribute to tumor cell destruction. Preliminary studies in humans show that IP(6) and inositol, the precursor molecule of IP(6), appear to enhance the anticancer effect of conventional chemotherapy, control cancer metastases, and improve quality of life. Because it is abundantly present in regular diet, efficiently absorbed from the gastrointestinal tract, and safe, IP(6) + inositol holds great promise in our strategies for cancer prevention and therapy. There is clearly enough evidence to justify the initiation of full-scale clinical trials in humans.
Collapse
Affiliation(s)
- Ivana Vucenik
- Department of Pathology, University of Maryland School of Medicine, MD 21201, USA.
| | | |
Collapse
|
15
|
Lam S, McWilliams A, LeRiche J, MacAulay C, Wattenberg L, Szabo E. A phase I study of myo-inositol for lung cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 2006; 15:1526-31. [PMID: 16896044 DOI: 10.1158/1055-9965.epi-06-0128] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
INTRODUCTION A phase I, open-label, multiple dose, dose-escalation clinical study was conducted to assess the safety, tolerability, maximum tolerated dose, and potential chemopreventive effect of myo-inositol in smokers with bronchial dysplasia. MATERIALS AND METHODS Smokers between 40 and 74 years of age with >or= 30 pack-years of smoking history and one or more sites of bronchial dysplasia were enrolled. A dose escalation study ranging from 12 to 30 g/d of myo-inositol for a month was first conducted in 16 subjects to determine the maximum tolerated dose. Ten new subjects were then enrolled to take the maximum tolerated dose for 3 months. The potential chemopreventive effect of myo-inositol was estimated by repeat autofluorescence bronchoscopy and biopsy. RESULTS The maximum tolerated dose was found to be 18 g/d. Side effects, when present, were mild and mainly gastrointestinal in nature. Using the regression rate of the placebo subjects from a recently completed clinical trial with the same inclusion/exclusion criteria as a comparison, a significant increase in the rate of regression of preexisting dysplastic lesions was observed (91% versus 48%; P = 0.014). A statistically significant reduction in the systolic and diastolic blood pressures by an average of 10 mm Hg was observed after taking 18 g/d of myo-inositol for a month or more. CONCLUSION myo-Inositol in a daily dose of 18 g p.o. for 3 months is safe and well tolerated. The potential chemopreventive effect as well as other health benefits such as reduction in blood pressure should be investigated further.
Collapse
Affiliation(s)
- Stephen Lam
- Department of Respiratory Medicine, British Columbia Cancer Agency, British Columbia, Canada.
| | | | | | | | | | | |
Collapse
|
16
|
Quintana-Espinoza P, Yáñez C, Escobar C, Sicker D, Araya-Maturana R, Squella J. Electrochemical Approach to the Radical Anion Formation from 2′-Hydroxy Chalcone Derivatives. ELECTROANAL 2006. [DOI: 10.1002/elan.200503422] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
17
|
Vucenik I, Shamsuddin AM. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. J Nutr 2003; 133:3778S-3784S. [PMID: 14608114 DOI: 10.1093/jn/133.11.3778s] [Citation(s) in RCA: 173] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Inositol hexaphosphate (IP6) is a naturally occurring polyphosphorylated carbohydrate that is present in substantial amounts in almost all plant and mammalian cells. It was recently recognized to possess multiple biological functions. A striking anticancer effect of IP6 was demonstrated in different experimental models. Inositol is also a natural constituent possessing moderate anticancer activity. The most consistent and best anticancer results were obtained from the combination of IP6 plus inositol. In addition to reducing cell proliferation, IP6 increases differentiation of malignant cells, often resulting in a reversion to normal phenotype. Exogenously administered IP6 is rapidly taken into the cells and dephosphorylated to lower-phosphate inositol phosphates, which further interfere with signal transduction pathways and cell cycle arrest. Enhanced immunity and antioxidant properties can also contribute to tumor cell destruction. However, the molecular mechanisms underlying this anticancer action are not fully understood. Because it is abundantly present in regular diet, efficiently absorbed from the gastrointestinal tract, and safe, IP6 holds great promise in our strategies for the prevention and treatment of cancer. IP6 plus inositol enhances the anticancer effect of conventional chemotherapy, controls cancer metastases, and improves the quality of life, as shown in a pilot clinical trial. The data strongly argue for the use of IP6 plus inositol in our strategies for cancer prevention and treatment. However, the effectiveness and safety of IP6 plus inositol at therapeutic doses needs to be determined in phase I and phase II clinical trials in humans.
Collapse
Affiliation(s)
- Ivana Vucenik
- Department of Medical and Research Technology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
| | | |
Collapse
|
18
|
Abstract
Lung cancer is the leading cause of cancer-related death in the world. Tobacco is an addictive agent producing carcinogenic effects that have been extremely difficult to prevent or detect in a curable stage. Important randomized controlled studies have been published in "healthy" smokers (primary prevention); patients with early lesions, such as mucosal dysplasia/metaplasia (secondary prevention); and those who have already had definitive treatment for their first tobacco-related malignancy (tertiary prevention). To date, the results have been generally disappointing. It is critical to remember that lung cancer is usually diagnosed decades after the patient has begun or even stopped smoking. We must intervene with more effective agents or combinations of agents and do it earlier in the process of carcinogenesis. Approximately 10% of patients with lung cancer either never smoked or only were "passive" smokers due to their environment, workplace. These "never-smokers" may actually benefit from retinoids, while current smokers have not benefited from alpha-tocopherol, retinal, N-acetylcysteine, or isotretinoin. Smokers are actually harmed by the concurrent use of beta-carotene. We now have unprecedented knowledge regarding the control of cellular growth and senescence. New diagnostic tools also allow detection of smaller lesions. We must use all our knowledge of the cancer biology, new risk models, more refined intermediate markers, and modern detection tools to focus more clearly on the pathology of lung cancer and design research to ask more probing and relevant questions so we can begin to put an end to the worldwide scourge of this terrible killer.
Collapse
Affiliation(s)
- Daniel D Karp
- MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
| | | | | |
Collapse
|
19
|
Witschi H, Espiritu I, Suffia M, Pinkerton KE. Expression of cyclin D1/2 in the lungs of strain A/J mice fed chemopreventive agents. Carcinogenesis 2002; 23:289-94. [PMID: 11872634 DOI: 10.1093/carcin/23.2.289] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Male strain A mice were fed a diet containing chemopreventive agents. After 1 and 3 weeks on the diets, lung nuclear fractions were examined for expression of cyclin D1/2 with western blot analysis. In animals fed a diet containing a mixture of myoinositol and dexamethasone, a treatment found previously to be effective in preventing the development of tobacco smoke-induced lung tumors in A/J mice, cyclin D1/2 expression was reduced to 30-40% of control levels. A similar decrease in cyclin D1/2 expression was found when animals were fed either myoinositol or dexamethasone alone. Paradoxically, tobacco smoke by itself had a similar effect on cyclin D1/2 expression. On the other hand, several agents that had been previously found not to be effective against tobacco smoke carcinogenesis [phenethyl isothiocyanate, 1,4-phenylenebis(methylene)selenoisocyanate, N-acetylcysteine, acetylsalicylic acid, D-limonene and beta carotene] did not decrease cyclin D1/2 expression after 1 or 3 weeks of feeding. It was concluded that expression of cyclin D1/2 might be a potentially useful marker in the identification of chemopreventive agents for tobacco smoke and could be of some help in the evaluation of their effects.
Collapse
Affiliation(s)
- Hanspeter Witschi
- Center for Health and the Environment and Department of Molecular Biosciences, School of Veterinary Medicine, University of California, One Shields Avenue, Davis, CA 95616, USA.
| | | | | | | |
Collapse
|
20
|
Kohno H, Yamaguchi K, Taima M, Tanaka T. Prevention of Colonic Aberrant Crypt Foci by Dietary Feeding of Chalcone and 2-Hydroxychalcone in Male F344 Rats. J Toxicol Pathol 2002. [DOI: 10.1293/tox.15.137] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Hiroyuki Kohno
- The First Department of Pathology, Kanazawa Medical University
| | - Kazue Yamaguchi
- The First Department of Pathology, Kanazawa Medical University
| | - Miki Taima
- The First Department of Pathology, Kanazawa Medical University
| | - Takuji Tanaka
- The First Department of Pathology, Kanazawa Medical University
| |
Collapse
|
21
|
Abstract
Colorectal cancer is a significant cause of mortality in Western societies. The progression of the disease from normal colonic epithelium to the acquisition of the malignant phenotype is accompanied by numerous genetic and epigenetic alterations. Compelling experimental and epidemiological evidence indicates that diet and nutrition are key factors in the modulation of colorectal cancer. A salient case in point is the recent observation that a dietary regimen based on a Western-style diet provokes in the rodent colon the appearance of preneoplastic lesions in the absence of any genotoxic insult. This review mainly describes dietary factors that inhibit the development and progression of colorectal cancer. Much is unknown about the precise mechanisms of action of chemically disparate nutrients and how they interfere with the development and progression of this disease. Current knowledge about this important issue is summarized. We believe that continuing scrutiny and precise assessment of the benefits (and potential risks) of nutrients in the treatment and prevention of colorectal cancer will prove significant to controlling this devastating disease.
Collapse
Affiliation(s)
- M Lipkin
- Strang Cancer Prevention Center, New York, USA.
| | | | | | | |
Collapse
|
22
|
Caltagirone S, Ranelletti FO, Rinelli A, Maggiano N, Colasante A, Musiani P, Aiello FB, Piantelli M. Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer. Am J Respir Cell Mol Biol 1997; 17:51-9. [PMID: 9224209 DOI: 10.1165/ajrcmb.17.1.2728] [Citation(s) in RCA: 72] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
The antiestrogen tamoxifen is thought to antagonize the effects of estrogens by competing with them for estrogen receptor (ER) binding. However, tarnoxifen can also reverse multidrug resistance, synergize with cisplatin cytotoxicity, and inhibit growth in ER-negative lung cancer cells. In addition to ERs, rat and human target tissues contain a second binding macromolecule termed the type II estrogen binding site (type II EBS). It has been shown that tamoxifen and flavonoids, a widely distributed class of natural substances with a variety of biologic actions, bind to type II EBS and inhibit the growth of several tumor cell types. At present, conflicting data about ERs and an absence of data about type II EBSs exist for lung tumors. We have tested non-small-cell lung carcinoma cell lines and primary tumor cells for the presence of ERs and type II EBSs and have evaluated the effects of tamoxifen and quercetin (pentahydroxyflavone) on the growth of these cells. Using a whole-cell assay and nuclear and cytosolic radiobinding experiments with [3H]estradiol as tracer, we have found that SK-LU1, SW900, ChaGo-K-1, H441, H661, and A549 cells, as well as primary tumors, bind estrogen specifically. This binding results mainly from the presence of a large number of type II EBSs, whereas ERs are absent or present at low concentrations. Type II EBSs bound tamoxifen and quercetin with similar affinity. Cell counts and a thymidine incorporation assay showed that both compounds inhibit cell growth in a concentration-dependent manner at concentrations ranging from 10 nM to 1 microM. Neither ipriflavone, an isoflavone, nor rutin, the 3-rhamnosylglucoside of quercetin, bound type II EBSs or inhibited cell growth. These findings suggest that tamoxifen and quercetin could regulate lung cancer cell growth through a binding interaction with type II EBSs. This mechanism could also be active in vivo, in that we have observed that nuclear and cytosolic type II EBSs were present in all primary lung cancers tested (n = 12), and that tamoxifen and quercetin were effective in inhibiting in vitro bromodeoxyuridine (BrdU) incorporation and proliferation-cell nuclear antigen expression by neoplastic cells in these cancers.
Collapse
Affiliation(s)
- S Caltagirone
- Department of Pathology, Gabriele D'Annunzio University, Chieti, Italy
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Kamei H, Koide T, Hashimoto Y, Kojima T, Hasegawa M. Tumor cell growth suppression by chalcone (1,3-diphenyl-2-propen-1-one). Cancer Biother Radiopharm 1997; 12:51-4. [PMID: 10851447 DOI: 10.1089/cbr.1997.12.51] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Chalcone or 1,3-diphenyl-2-propen-1-one which is widely distributed in higher plants and is considered to be a precursor of all flavonoids, was studies in terms of its anti-tumor growth activity in vitro and in vivo. Mice given the chalcone, which was suspended in the drinking water, showed a statistically significant rise in percent survival: 66% at the 35th day for the chalcone-treated animals vs. 30% for the control ones. The chalcone also gave significant suppression of growth of HCT-15 and Meth/A cells in vitro. The dose of 50% reduction in growth was between 2.5 micrograms/ml and 0.6 microgram/ml for the HCT-15 cells and less than 10 micrograms/ml for the Meth/A cells. Histograms obtained by flow cytometric examination showed an elevated region between the diploid and the tetra-ploid nucleoidal peaks. A third peak heavier than the tetra-ploid peak was also observed, which peak was not observed in the control. The percentage of cells in the S phase was significantly raised. Microscopically, large nucleated cells were observed following addition of the chalcone. These results suggest that the chalcone induced abnormal DNA synthesis and mitosis in the cultured cells.
Collapse
Affiliation(s)
- H Kamei
- Dept. of Surgery, Aichi-Gakuin University Hospital, Nagoya, Japan
| | | | | | | | | |
Collapse
|
24
|
Abstract
Inositol hexaphosphate (InsP6 or IP6) is ubiquitous. At 10 microM to 1 mM concentrations, IP6 and its lower phosphorylated forms (IP(1-5)) as well as inositol (Ins) are contained in most mammalian cells, wherein they are important in regulating vital cellular functions such as signal transduction, cell proliferation and differentiation. A striking anti-cancer action of IP6 has been demonstrated both in vivo and in vitro, which is based on the hypotheses that exogenously administered IP6 may be internalized, dephosphorylated to IP(1-5), and inhibit cell growth. There is additional evidence that Ins alone may further enhance the anti-cancer effect of IP6. Besides decreasing cellular proliferation, IP6 also causes differentiation of malignant cells often resulting in a reversion to normal phenotype. These data strongly point towards the involvement of signal transduction pathways, cell cycle regulatory genes, differentiation genes, oncogenes and perhaps, tumor suppressor genes in bringing about the observed anti-neoplastic action of IP6.
Collapse
Affiliation(s)
- A M Shamsuddin
- University of Maryland School of Medicine, Baltimore 21201-1192, U.S.A
| | | | | |
Collapse
|
25
|
Affiliation(s)
- L W Wattenberg
- Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis 55455, USA
| |
Collapse
|